PMID- 24880240
OWN - NLM
STAT- MEDLINE
DCOM- 20150911
LR  - 20221207
IS  - 1559-1166 (Electronic)
IS  - 0895-8696 (Linking)
VI  - 55
IP  - 2
DP  - 2015 Feb
TI  - Citalopram protects against cold-restraint stress-induced activation of 
      brain-derived neurotrophic factor and expression of nuclear factor 
      kappa-light-chain-enhancer of activated B cells in rats.
PG  - 355-66
LID - 10.1007/s12031-014-0334-3 [doi]
AB  - The present study evaluates the protective effect of citalopram against 
      cold-restraint stress (CRS) paradigm. Rats were pretreated with citalopram (0.1, 
      1.0, and 10.0 mg/kg) acutely and repeatedly for 21 days before exposure to the 
      CRS procedure. None of the doses of citalopram attenuated CRS-induced gastric 
      ulcers in the acute study. In contrast, repeated pretreatment of citalopram at a 
      dose level of 0.1 mg/kg attenuated the CRS-induced gastric ulcers. Citalopram 
      (0.1 mg/kg) diminished CRS-induced increase in plasma corticosterone, but not 
      plasma norepinephrine level in the chronic study indicating its effect on 
      hypothalamic-pituitary-adrenal axis function. Repeated citalopram (0.1 mg/kg) 
      pretreatment attenuated CRS-induced changes in serotonin turnover in the 
      hippocampus and amygdala. Moreover, repeated pretreatment with citalopram (0.1 
      mg/kg) mitigated the CRS-induced increase in the expression of brain-derived 
      neurotrophic factor (BDNF) and nuclear factor kappa-light-chain-enhancer of 
      activated B cells (NFkappaB) in the hippocampus and amygdala. These results suggest 
      that there is a region- and a dose-specific effect of citalopram on CRS-induced 
      BDNF-NFkappaB activation. Therefore, citalopram showed antistress activity in the CRS 
      model through changes in the stress-responsive pathways such as 
      hypothalamic-pituitary-adrenal-axis and brain serotonergic system apart from 
      decreasing the expression of BDNF and NFkappaB.
FAU - Garabadu, Debapriya
AU  - Garabadu D
AD  - Neurotherapeutics Lab, Department of Pharmaceutics, Indian Institute of 
      Technology (Banaras Hindu University), Varanasi, 221005, India.
FAU - Reddy, B C M Harshavardhan
AU  - Reddy BC
FAU - Krishnamurthy, Sairam
AU  - Krishnamurthy S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140601
PL  - United States
TA  - J Mol Neurosci
JT  - Journal of molecular neuroscience : MN
JID - 9002991
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (NF-kappa B)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 333DO1RDJY (Serotonin)
RN  - W980KJ009P (Corticosterone)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Amygdala/drug effects/metabolism
MH  - Animals
MH  - B-Lymphocytes/*drug effects/metabolism
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism
MH  - Citalopram/*pharmacology/therapeutic use
MH  - *Cold-Shock Response
MH  - Corticosterone/blood
MH  - Hippocampus/drug effects/metabolism
MH  - Male
MH  - NF-kappa B/genetics/*metabolism
MH  - Norepinephrine/blood
MH  - Rats
MH  - Serotonin/blood
MH  - Selective Serotonin Reuptake Inhibitors/*pharmacology/therapeutic use
MH  - Stress, Psychological/complications/*drug therapy/metabolism
EDAT- 2014/06/02 06:00
MHDA- 2015/09/12 06:00
CRDT- 2014/06/02 06:00
PHST- 2014/02/28 00:00 [received]
PHST- 2014/05/15 00:00 [accepted]
PHST- 2014/06/02 06:00 [entrez]
PHST- 2014/06/02 06:00 [pubmed]
PHST- 2015/09/12 06:00 [medline]
AID - 10.1007/s12031-014-0334-3 [doi]
PST - ppublish
SO  - J Mol Neurosci. 2015 Feb;55(2):355-66. doi: 10.1007/s12031-014-0334-3. Epub 2014 
      Jun 1.